Cost‐Effectiveness of Diabetes Case Management for Low‐Income Populations
- 16 February 2007
- journal article
- Published by Wiley in Health Services Research
- Vol. 42 (5) , 1943-1959
- https://doi.org/10.1111/j.1475-6773.2007.00701.x
Abstract
Objective. To evaluate the cost-effectiveness of Project Dulce, a culturally specific diabetes case management and self-management training program, in four cohorts defined by insurance status. Data Sources/Study Setting. Clinical and cost data on 3,893 persons with diabetes participating in Project Dulce were used as inputs into a diabetes simulation model. Study Design. The Center for Outcomes Research Diabetes Model, a published, peer-reviewed and validated simulation model of diabetes, was used to evaluate life expectancy, quality-adjusted life expectancy (QALY), cumulative incidence of complications and direct medical costs over patient lifetimes (40-year time horizon) from a third-party payer perspective. Cohort characteristics, treatment effects, and case management costs were derived using a difference in difference design comparing data from the Project Dulce program to a cohort of historical controls. Long-term costs were derived from published U.S. sources. Costs and clinical benefits were discounted at 3.0 percent per annum. Sensitivity analyses were performed. Principal Findings. Incremental cost-effectiveness ratios of $10,141, $24,584, $44,941, and $69,587 per QALY gained were estimated for Project Dulce participants versus control in the uninsured, County Medical Services, Medi-Cal, and commercial insurance cohorts, respectively. Conclusions. The Project Dulce diabetes case management program was associated with cost-effective improvements in quality-adjusted life expectancy and decreased incidence of diabetes-related complications over patient lifetimes. Diabetes case management may be particularly cost effective for low-income populations.Keywords
This publication has 23 references indexed in Scilit:
- Commentary-Response to Richard KronickHealth Services Research, 2006
- Commentary—Sophisticated Methods but Implausible Results: How Much Does Health Insurance Improve Health?Health Services Research, 2006
- Health Insurance and Health at Age 65: Implications for Medical Care Spending on New Medicare BeneficiariesHealth Services Research, 2006
- Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UKDiabetic Medicine, 2005
- Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trialsCurrent Medical Research and Opinion, 2004
- Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 DiabetesCurrent Medical Research and Opinion, 2004
- Validation of the CORE Diabetes Model Against Epidemiological and Clinical StudiesCurrent Medical Research and Opinion, 2004
- Closing the Gap: Effect of Diabetes Case Management on Glycemic Control Among Low-Income Ethnic Minority PopulationsDiabetes Care, 2004
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- Standards of Medical Care for Patients With Diabetes MellitusDiabetes Care, 2003